Literature DB >> 29242725

68Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer.

Christoph-Alexander J von Klot1, Axel S Merseburger2, Alena Böker1, Sebastian Schmuck3, Tobias L Ross3, Frank M Bengel3, Markus A Kuczyk1, Christoph Henkenberens4, Hans Christiansen4, Hans-Jürgen Wester5, Wiebke Solass6, Marcel Lafos6, Thorsten Derlin3.   

Abstract

PURPOSE: 68Ga-labeled prostate-specific membrane antigen (PSMA) ligand positron emission tomography/computed tomography (PET/CT) has shown promising results in patients with biochemical recurrence after primary therapy for prostate cancer. In this study, we evaluated the usefulness of PSMA I&T (imaging and therapy) PET/CT prior to radical prostatectomy.
METHODS: The study population consisted of 21 patients with prostate cancer who underwent 68Ga-PSMA I&T PET/CT before either open or laparoscopic radical prostatectomy. Intraprostatic tumor extent, extracapsular extension (ECE) and seminal vesicle invasion (SVI) were assessed on the PET/CT scans. Tracer uptake was quantified in terms of standardized uptake values (SUVs). Imaging findings were correlated with final whole-gland histopathology.
RESULTS: Of the 21 patients, two had T stage 2b disease, nine stage 2c, six stage 3a and four stage 3b. The median Gleason score was 7. The SUVmean of the primary tumors was 9.5 ± 8.8. SUVmean was higher in tumors with ECE than in organ-confined tumors (13.8 ± 11.0 vs. 5.6 ± 3.2, p = 0.029). Peak tracer uptake was significantly positively correlated with Gleason score (rs = 0.49, p = 0.025). Sensitivity, specificity, positive predictive value and negative predictive value were, respectively, 94.7%, 75.0%, 97.3% and 60.0% for tumor infiltration of an individual prostate lobe, 75.0%, 100.0%, 100.0% and 97.4% for SVI, and 90.0%, 90.9%, 90.0% and 90.9% for ECE, using an angulated contour of the prostate as the criterion. Tumor volume derived from 68Ga-PSMA I&T PET/CT was significantly correlated with preoperative prostate-specific antigen value (rp = 0.75, p < 0.001) and tumor volume on histopathology (rp = 0.45, p = 0.039).
CONCLUSIONS: 68Ga-PSMA I&T PET/CT prior to radical prostatectomy can contribute to presurgical local staging of prostate cancer. In this pilot study, 68Ga-PSMA I&T PET/CT showed promising results for prediction of lobe infiltration, ECE and SVI.

Entities:  

Keywords:  Extracapsular extension; PET/CT; Prostate cancer; Prostate-specific membrane antigen (PSMA); Seminal vesicle; Staging

Year:  2017        PMID: 29242725      PMCID: PMC5721087          DOI: 10.1007/s13139-017-0476-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  32 in total

1.  Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience.

Authors:  A Afshar-Oromieh; U Haberkorn; H P Schlemmer; M Fenchel; M Eder; M Eisenhut; B A Hadaschik; A Kopp-Schneider; M Röthke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-19       Impact factor: 9.236

2.  Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.

Authors:  John F Ward; Jeffrey M Slezak; Michael L Blute; Erik J Bergstralh; Horst Zincke
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

3.  Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer.

Authors:  Michael Mullerad; Hedvig Hricak; Kentaro Kuroiwa; Darko Pucar; Hui-Ni Chen; Michael W Kattan; Peter T Scardino
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

4.  Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.

Authors:  Stephen J Freedland; George S Csathy; Frederick Dorey; William J Aronson
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

5.  Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy.

Authors:  Lars Budäus; Sami-Ramzi Leyh-Bannurah; Georg Salomon; Uwe Michl; Hans Heinzer; Hartwig Huland; Markus Graefen; Thomas Steuber; Clemens Rosenbaum
Journal:  Eur Urol       Date:  2015-06-25       Impact factor: 20.096

6.  Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy.

Authors:  Ken Herrmann; Christina Bluemel; Martina Weineisen; Margret Schottelius; Hans-Jürgen Wester; Johannes Czernin; Uta Eberlein; Seval Beykan; Constantin Lapa; Hubertus Riedmiller; Markus Krebs; Saskia Kropf; Andreas Schirbel; Andreas K Buck; Michael Lassmann
Journal:  J Nucl Med       Date:  2015-04-16       Impact factor: 10.057

7.  High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer.

Authors:  Sarah Minner; Corinna Wittmer; Markus Graefen; Georg Salomon; Thomas Steuber; Alexander Haese; Hartwig Huland; Carsten Bokemeyer; Emre Yekebas; Judith Dierlamm; Stefan Balabanov; Ergin Kilic; Waldemar Wilczak; Ronald Simon; Guido Sauter; Thorsten Schlomm
Journal:  Prostate       Date:  2010-08-31       Impact factor: 4.104

8.  Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer.

Authors:  Stacy Loeb; Norm D Smith; Kimberly A Roehl; William J Catalona
Journal:  Urology       Date:  2007-06       Impact factor: 2.649

9.  Multimodal image-guided prostate fusion biopsy based on automatic deformable registration.

Authors:  Oliver Zettinig; Amit Shah; Christoph Hennersperger; Matthias Eiber; Christine Kroll; Hubert Kübler; Tobias Maurer; Fausto Milletarì; Julia Rackerseder; Christian Schulte Zu Berge; Enno Storz; Benjamin Frisch; Nassir Navab
Journal:  Int J Comput Assist Radiol Surg       Date:  2015-06-09       Impact factor: 2.924

10.  Is Prebiopsy MRI Good Enough to Avoid Prostate Biopsy? A Cohort Study Over a 1-Year Period.

Authors:  Benjamin W Lamb; Wei Shen Tan; Attia Rehman; Afsara Nessa; Daniel Cohen; John O'Neil; James S A Green; John E W Hines
Journal:  Clin Genitourin Cancer       Date:  2015-06-30       Impact factor: 2.872

View more
  10 in total

1.  18F-Fluciclovine versus PSMA PET Imaging in Primary Tumor Detection during Initial Staging of High-Risk Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Divya Yadav; Hyunsoo Hwang; Wei Qiao; Rituraj Upadhyay; Brian F Chapin; Chad Tang; Ana Aparicio; Maria A Lopez-Olivo; Stella K Kang; Homer A Macapinlac; Tharakeswara K Bathala; Devaki Shilpa Surasi
Journal:  Radiol Imaging Cancer       Date:  2022-03

2.  68Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.

Authors:  Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Niels J Rupp; Martin Huellner; Michael Messerli; Jan Hendrik Rüschoff; Edwin E G W Ter Voert; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-14       Impact factor: 9.236

3.  Time point-independent tumor positivity of 68Ga-PSMA-PET/CT pre- and post-biopsy in high-risk prostate cancer.

Authors:  Sijuan Zou; Shuang Song; Jianyuan Zhou; Bo Yu; Dong Kuang; Zhihua Wang; Xiaohua Zhu
Journal:  Ann Nucl Med       Date:  2022-04-01       Impact factor: 2.258

4.  Comparison of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and multi-parametric magnetic resonance imaging (MRI) in the evaluation of tumor extension of primary prostate cancer.

Authors:  Mengxia Chen; Qing Zhang; Chengwei Zhang; Yi-Hua Zhou; Xiaozhi Zhao; Yao Fu; Jie Gao; Bing Zhang; Feng Wang; Xuefeng Qiu; Hongqian Guo
Journal:  Transl Androl Urol       Date:  2020-04

5.  Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative 68Ga-PSMA-11 PET/CT.

Authors:  Xuefeng Qiu; Mengxia Chen; Haoli Yin; Qing Zhang; Haoyang Li; Suhan Guo; Yao Fu; Shiming Zang; Shuyue Ai; Feng Wang; Hongqian Guo
Journal:  Front Oncol       Date:  2021-09-30       Impact factor: 6.244

Review 6.  Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis.

Authors:  Sui Wai Ling; Anouk C de Jong; Ivo G Schoots; Kazem Nasserinejad; Martijn B Busstra; Astrid A M van der Veldt; Tessa Brabander
Journal:  Eur Urol Open Sci       Date:  2021-09-28

7.  Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients.

Authors:  Riccardo Laudicella; Stephan Skawran; Daniela A Ferraro; Urs J Mühlematter; Alexander Maurer; Hannes Grünig; Hendrik J Rüschoff; Niels Rupp; Olivio Donati; Daniel Eberli; Irene A Burger
Journal:  Insights Imaging       Date:  2022-04-15

8.  Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.

Authors:  Sungmin Woo; Soleen Ghafoor; Anton S Becker; Sangwon Han; Andreas G Wibmer; Hedvig Hricak; Irene A Burger; Heiko Schöder; Hebert Alberto Vargas
Journal:  Eur J Hybrid Imaging       Date:  2020-09-09

Review 9.  Clinical perspectives of PSMA PET/MRI for prostate cancer.

Authors:  Felipe de Galiza Barbosa; Marcelo Araújo Queiroz; Rafael Fernandes Nunes; José Flávio Gomes Marin; Carlos Alberto Buchpiguel; Giovanni Guido Cerri
Journal:  Clinics (Sao Paulo)       Date:  2018-09-21       Impact factor: 2.365

10.  Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.

Authors:  B H E Jansen; Y J L Bodar; G J C Zwezerijnen; D Meijer; J P van der Voorn; J A Nieuwenhuijzen; M Wondergem; T A Roeleveld; R Boellaard; O S Hoekstra; R J A van Moorselaar; D E Oprea-Lager; A N Vis
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-08-12       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.